Prescription of Antibiotics in Intensive Care Units in Latin America: An Observational Study

REFERENCES

• Roder BL, Nielsen SL, Magnussen P, Engquist A, Frimodt-Moller N.Antibiotic usage in an intensive care unit in a Danish university hospital. J Antimicrob Chemother. 1993; 32 (4): 633–42.
   PubMed Web of Science ®Google Scholar
• Monnet DL, Archibald LK, Phillips L, Tenover FC, Mc-Gowan JE Jr, Gaynes RP.Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modeling. In-tensive Care Antimicrobial Resistance Epidemiology Project and National Nosocomial Infections Surveillance System Hospitals. Infect Control Hosp Epidemiol. 1998; 19 (6): 388-94.
   Google Scholar
• Rogues AM, Dumartin C, Amadéo B, Venier AG, Marty N, Parneix P, et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol. 2007;28 (12): 1389–95.
   PubMed Web of Science ®Google Scholar
• Iosifidis E, Antachopoulos C, Tsivitanidou M, Katragkou A, Farmaki E, Tsiakou M, et al. Differential correlation between rates of antimicrobial drug consumption and prevalence of an-timicrobial resistance in a tertiary care hospital in Greece. Infect Control Hosp Epidemiol. 2008; 29 (7): 615–22.
   PubMed Web of Science ®Google Scholar
• Fujimura S, Nakano Y, Sato T, Shirahata K, Watanabe A. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa. J Infect Chemother. 2007; 13 (3): 147–50.
   PubMedGoogle Scholar
• Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079–81.
   PubMed Web of Science ®Google Scholar
• T.E.S.T. program (Tigecycline Evaluation and Surveillance Trial). www.testsurveillance.com; last access January 7, 2009.
   Google Scholar
• Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of blood-stream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146–155.
   PubMed Web of Science ®Google Scholar
• Rello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 196–200.
   PubMed Web of Science ®Google Scholar
• Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676–685.
   PubMed Web of Science ®Google Scholar
• Elhanan G, Sarhat M, Raz R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in Patients with community-acquired bacteraemia due to urinary tract infection. J Infect. 1997; 35 (3): 283–8.
   PubMed Web of Science ®Google Scholar
• Rintala E, Kairisto V, Eerola E, Nikoskelainen J, Lehto-nen OP. Antimicrobial therapy of septicemic patients in inten-sive care units before and after blood culture reporting. Scand J Infect Dis. 1991; 23 (3): 341–6.
   PubMed Web of Science ®Google Scholar
• Esposito S, Leone S. Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious dis-ease specialist. Int J Antimicrob Agents. 2007; 29 (5): 494–500.
   PubMed Web of Science ®Google Scholar
• McQuillen DP, Petrak RM, Wasserman RB, Nahass RG, Scull JA, Martinelli LP. The value of infectious diseases special-ists: non-patient care activities. Clin Infect Dis. 2008; 47 (8): 1051–63.
   PubMed Web of Science ®Google Scholar
• Raineri E, Pan A, Mondello P, Acquarolo A, Candiani A, Crema L. Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. Am J Infect Control. 2008; 36 (4): 283–90.
   PubMed Web of Science ®Google Scholar
• Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128–40.
   PubMed Web of Science ®Google Scholar
• Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: variability by site of in-fection. Arch. Intern. Med. 2005; 165: 175–180.
   Google Scholar
• Krieg NR, Holt JG. Bergey's Manual of Systematic Bac-teriology, Volume 1. Baltimore, MD, USA: Williams & Wilkins, 1984.
   Google Scholar
• Clinical and Laboratory Standard Institute, Wayne, PA. CLSI document. Clinical and Laboratory Standard Methods. Per-formance standards for antimicrobial susceptibility testing: 17th informational supplement; 2007: M100-517.
   Google Scholar
• Bergmans DC, Bonten MJ, Gaillard CA, van Tiel FH, van der Geest S, de Leeuw PW, et al. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother. 1997; 39 (4): 527–35.
   PubMed Web of Science ®Google Scholar
• Nguyen HB, Rivers EP, Havstad S, Knoblich B, Ressler JA, Muzzin AM, et al. Critical care in the emergency department: A physiologic assessment and outcome evaluation. Acad Emerg Med. 2000; 7 (12): 1354–61.
   PubMed Web of Science ®Google Scholar
• Cuthbertson BH, Thompson M, Sherry A, Wright MM, Bellingan GJ; Intensive Care Society. Antibiotic-treated infections in intensive care patients in the UK. Anaesthesia, 2004, 59: 885–890.
   PubMed Web of Science ®Google Scholar
• Schurink CA, Hoitsma M, Rozenberg-Arska M, Joore JC, Hoepelman IM, Bonten MJ. Do cultures contribute to optimisa-tion of antibiotic therapy in the intensive care unit? Int J Antimi-crob Agents. 2004; 23 (4): 325–31.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial in-fection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC In-ternational Advisory Committee. JAMA 1995; 274: 639–44.
   Google Scholar
• Richards GA. The therapeutic challenge of Gram-negative sepsis: prolonging the lifespan of a scarce resource. Clin Micro-biol Infect. 2005;11 Suppl 6: 18–22.
   PubMedGoogle Scholar
• Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC; SENTRY Participants Group (Latin America). SENTRY antimi-crobial surveillance program report: Latin American and Brazil-ian results for 1997 through 2001. Braz J Infect Dis. 2004; 8 (1): 25-79.
   PubMedGoogle Scholar
• Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991: 115: 585–590.
   Google Scholar
• Celis R, Torres A, Gatell JM, Almela M, Rodriguez-Roisin R, Agusti-Vidal A. Nosocomial pneumonia. A multivariate analy-sis of risk and prognosis. Chest 1988: 93: 318–324.
   Google Scholar
• Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Dame C, et al. Nosocomial pneumonia in patients receiving con-tinuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989: 139: 877–884.
   Google Scholar
• Mentzelopoulos SD, Pratikaki M, Platsouka E, Kraniotaki H, Zervakis D, Koutsoukou A, et al. Prolonged use of carbapen-ems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med. 2007; 33 (9): 1524–32.
   PubMed Web of Science ®Google Scholar
• Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, et al. Citywide clonal outbreak of multiresis-tant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med. 2002; 162 (13): 1515–20.
   PubMedGoogle Scholar
• Saurina G, Quale JM, Manikal VM, Oydna E, Landman D. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J Antimi-crob Chemother. 2000; 45 (6): 895–8.
   PubMed Web of Science ®Google Scholar
• Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of blood-stream infections on patient outcomes in the ICU setting. Chest 2000; 118 (1): 146–155.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115 (2): 462–474.
   PubMed Web of Science ®Google Scholar
• Kollef MH. Inadequate antimicrobial treatment: an impor-tant determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31 Suppl 4:S131–S138.
   PubMedGoogle Scholar
• Roger PM, Hyvernat H, Verleine-Pugliese S, Bourroul C, Giordano J, Fosse T, et al. Systematic infection consultation in the intensive care unit. Impact of shortterm antibiotic use. Presse Med 2000; 29: 1640–4.
   PubMed Web of Science ®Google Scholar
• Byl B, Clevenbergh P, Jacobs F, Struelens MJ, Zech F, Kentos A, et al. Impact of infectious diseases specialists and mi-crobiological data on the appropriateness of antimicrobial ther-apy for bacteremia. Clin Infect Dis 1999; 29: 60–6.
   PubMed Web of Science ®Google Scholar
• Fox BC, Imrey PB, Voights MB, Norwood S. Infectious disease consultation and microbiologic surveillance for intensive care unit trauma patients: a pilot study. Clin Infect Dis 2001; 33: 1981–9.
   PubMed Web of Science ®Google Scholar
• Curcio D, Belloni R. Strategic alliance between the infec-tious diseases specialist and intensive care unit physician for change in antibiotic use. J Chemother. 2005 Feb; 17 (1): 74–6.
   PubMed Web of Science ®Google Scholar
• Gomez J, Conde Cavero SJ, Hernandez Cardona JL, Nunez ML, Ruiz Gomez J, Canteras M, et al. The influence of the opinion of an infectious disease consultant on the appropriate-ness of antibiotic treatment in a general hospital. J Antimicrob Chemother 1996; 38: 309–14.
   PubMed Web of Science ®Google Scholar
• Lemmen SW, Becker G, Frank U, Daschner FD. Influence of an infectious disease consulting service on quality and costs of antibiotic prescriptions in a university hospital. Scand J Infect Dis. 2001; 33 (3): 219–21.
   PubMedGoogle Scholar
• Fridkin SK, Steward CD, Edwards JR, Pryor ER, Mc-Gowan JE Jr, Archibald LK, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: proj-ect ICARE phase 2. Project Intensive Care Antimicrobial Resist-ance Epidemiology (ICARE) hospitals. Clin Infect Dis. 1999; 29 (2): 245-52.
   Google Scholar
• Tognim MC, Andrade SS, Silbert S, Gales AC, Jones RN, Sader HS. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY An-timicrobial Surveillance Program. Int J Infect Dis. 2004; 8 (5): 284–91.
   Google Scholar
• Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa iso-lates producing a KPC-type carbapenem-hydrolyzing beta-lacta-mase. Antimicrob Agents Chemother. 2007; 51 (4): 1553–5.
   PubMed Web of Science ®Google Scholar
• Villegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M, Quinn JP. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneu-moniae from South America. Antimicrob Agents Chemother. 2006 ; 50 (8): 2880–2.
   PubMed Web of Science ®Google Scholar
• Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC. First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. Antimicrob Agents Chemother. 2009; 53 (1): 333–4.
   PubMed Web of Science ®Google Scholar
• Peirano G, Seki LM, Val Passos VL, Pinto MC, Guerra LR, Asensi MD. Carbapenem-hydrolysing beta-lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil. J Antimicrob Chemother. 2009; 63 (2): 265–8.
   PubMed Web of Science ®Google Scholar
• Pasteran FG, Otaegui L, Guerriero L, Radice G, Maggiora R, Rapoport M, et al. Klebsiella pneumoniae Carbapenemase-2, Buenos Aires, Argentina. Emerg Infect Dis. 2008; 14 (7): 1178–80
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48 (1): 1–12.
   PubMed Web of Science ®Google Scholar
• Lima AL, Oliveira PR, Paula AP, Dal-Paz K, Rossi F, Zu-miotti AV. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: A Hospital Case Study. Infect Control Hosp Epidemiol. 2009; Mar 31. [Epub ahead of print]
   Google Scholar